Doxorubicin remains the gold standard in the first line chemotherapy for patients with advanced or metastatic soft tissue sarcoma
Long awaited results of the EORTC trial compared single agent doxorubicin versus doxorubicin plus ifosfamide
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Long awaited results of the EORTC trial compared single agent doxorubicin versus doxorubicin plus ifosfamide
Active hepatitis B virus (HBV) and hepatitis C virus (HCV) are highly prevalent around the world.
The European Society for Medical Oncology (ESMO) has awarded its ESMO Designated Centre of Integrated Oncology and Palliative Care accreditation to 16 new oncology centres
ESMO as an organisation is not shying away from the current global economic crisis and is conscious of the growing need to address issues of health economics in the field of oncology.
Results of the phase III SEARCH trial
With clinical research placing so much emphasis on the genetics of cancer, predictive biomarkers and the identification of molecular targets in tumour cells, it’s all too easy to forget that cancer cells also have ‘context’.
Spinal cord compression, pathological fracture and other skeletal-related events (SREs) feature prominently in patients with metastatic castration-resistant prostate cancer (mCRPC). The bisphosphonate, zoledronate, is widely, though not universally, regarded as a standard treatment to reduce the risk of SREs in these patients. However, new drugs are emerging suggesting that we may soon be able to offer a better standard of care for the prevention of SREs and metastatic bone pain
Following on from the positive data reported by Dr Alice Shaw on the Phase 3 trial of crizotinib as second-line therapy for patients with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC), findings from the European Thoracic Oncology Platform Lungscape Project, which is evaluating the prevalence of ALK positivity in resected stage I-III lung adenocarcinomas in Europe, were met with great interest.
Findings confirm the current standard duration of adjuvant trastuzumab for women with HER2-positive early breast cancer
Findings from the primary analysis of the randomized Phase 3, European intergroup PETACC8 trial, presented at ESMO 2012 by Dr Julien Taieb of the Georges Pompidou European Hospital, Paris, France, showed that the addition of cetuximab to standard adjuvant FOLFOX4 chemotherapy regimen offers no benefit to patients with resected stage III, KRAS wild-type (wt) colon cancer.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.